Esperion Therapeutics Bolsa (NASDAQ: ESPR)

Últimas noticias sobre Esperion Therapeutics (NASDAQ:ESPR) Bolsa

ESPERION THERAPEUTICS INC

Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics Inc

ESPRE TECHNOLOGIES INC B by ESPRE TECHNOLOGIES INC

Espre Technologies Inc

ESPRIT HOLDINS LTD by Esprit Holdings Ltd.

Esprit Holdings Ltd

ESPRIT HLDGS S/ADR by Esprit Holdings Ltd.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

News

Price Target

Reiteration

Analyst Ratings

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Esperion Announces Alignment With FDA On Path To Initiate Phase 3 Clinical Trials Of Bempedoic Acid Alone And In Combination With Ezetimibe

Citizens Capital Markets analyst Jason Butler reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Market Outperform and maintains $4 price target.

Citizens Capital Markets Reiterates Market Outperform on Esperion Therapeutics, Maintains $4 Price Target

WIIM

Esperion Therapeutics shares are trading higher after the company reported better than expected Q4 FY24 earnings.

Biotech

Earnings

Guidance

Health Care

General

Esperion Expects Full Year 2025 Operating Expenses Of $215M-$235M, Including Approximately $15M In Non-cash Expenses Related To Stock Compensation

Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 78 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $69.11 million which beat the analyst consensus estimate of $61.58 million by 12.22 percent. This is a 114.30 percent increase over sales of $32.25 million the same period last year.

Esperion Therapeutics Q4 2024 GAAP EPS $(0.11) Beats $(0.16) Estimate, Sales $69.11M Beat $61.58M Estimate

<h3>Companies Reporting Before The Bell</h3>
• 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is likely to report quarterly loss at $0.37 per share on revenue of $16.18 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is projected to report quarterly loss at $0.23 per share on revenue of $262.65 million. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its fourth quarter. 
• EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $69.00 million. 
• L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $131.48 million. 
• WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $25.59 million. 
• InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $34.40 million. 
• Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) is expected to report earnings for its fourth quarter. 
• Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.24 per share on revenue of $18.98 million. 
• Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $26.94 million. 
• Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $87.51 million. 
• Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $279.58 million. 
• Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $9.99 million. 
• Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $63.06 million. 
• Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is expected to report quarterly loss at $0.15 per share on revenue of $17.71 million. 
• Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $437.22 million. 
• Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly loss at $0.07 per share on revenue of $24.96 million. 
• Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $4.60 billion. 
• Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $175.71 million. 
• On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $593.34 million. 
• Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $91.89 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is likely to report quarterly earnings at $2.42 per share on revenue of $13.69 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $2.65 per share on revenue of $30.28 billion. 
• CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $118.97 million. 
• Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $290.88 million. 
• Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $11.86 million. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is estimated to report quarterly earnings at $29.90 per share on revenue of $4.00 billion. 
<h3>Companies Reporting After The Bell</h3>
• Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $53.66 million. 
• Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is projected to report quarterly loss at $0.49 per share on revenue of $230.13 million. 
• Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $41.00 million. 
• Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is projected to report earnings for its fourth quarter. 
• Baytex Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $980.40 million. 
• Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $26.54 million. 
• ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $26.52 million. 
• Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $57.60 million. 
• Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $194.91 million. 
• Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.63 million. 
• comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $91.66 million. 
• Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $8.78 million. 
• Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly loss at $0.08 per share on revenue of $124.13 million. 
• NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $21.11 million. 
• ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) is projected to report quarterly loss at $0.19 per share on revenue of $179.11 million. 
• Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is projected to report quarterly loss at $0.16 per share on revenue of $49.37 million. 
• OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is projected to report quarterly loss at $0.26 per share on revenue of $52.70 million. 
• Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report earnings for its fourth quarter. 
• Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $7.68 billion. 
• Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $25.68 million. 
• Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $16.92 million. 
• AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $214.00 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $5.95 billion. 
• Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $77.23 million. 
• Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is expected to report quarterly loss at $0.20 per share on revenue of $6.23 million. 
• CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is expected to report quarterly loss at $0.31 per share on revenue of $58.79 million. 
• Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $13.22 billion. 
• ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $100.97 million. 
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $120.31 million. 
• Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $15.64 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $1.03 billion. 
• Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $64.70 million. 
• Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $539.81 million. 
• Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $214.41 million. 
• Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $272.70 million. 
• Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $84.95 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $278.60 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $223.23 million. 
• Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $1.13 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $4.33 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACNT

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AOMR

ATNI

ATRO

AVAV

CDXC

CGEN

CHPT

CPIX

CRCT

CRDO

CRWD

CTOS

CXDO

CYRX

EOLS

EOSE

EVGO

FSTR

FTEK

GENI

GIFI

HGTY

HRZN

INFU

INGM

KIDS

MASS

MFIN

NPCE

Nuveen Arizona Dividend Advantage Municipal Funds 3

NYAX

OLPX

ONON

OOMA

OWLT

PLUG

PMTS

PSFE

RIGL

ROST

SCOR

SLND

SOPH

STEM

STIM

SWIM

TKNO

WEYS

YMAB

Earnings Scheduled For March 4, 2025

Esperion And CSL Seqirus Partners To Commercialize NEXLETOL And NEXLIZET In Australia

JMP Securities analyst Roy Buchanan maintains Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Market Outperform and lowers the price target from $7 to $4.

JMP Securities Maintains Market Outperform on Esperion Therapeutics, Lowers Price Target to $4

JMP Securities analyst Roy Buchanan reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Market Outperform and maintains $7 price target.

JMP Securities Reiterates Market Outperform on Esperion Therapeutics, Maintains $7 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) from Buy to Buy.

HC Wainwright & Co. Reiterates Buy on Esperion Therapeuticsto Buy

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –
– New Facility Represents $150 Million Strategic Investment Led by Healthcare Specialist Athyrium Capital Management and Joined by HealthCare Royalty –

Esperion Secures $250M In Refinancing To Strengthen Balance Sheet And Extend Debt Maturity

Goldman Sachs analyst Paul Choi reinstates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Neutral and announces $4 price target.

Initiation

Goldman Sachs Reinstates Neutral on Esperion Therapeutics, Announces $4 Price Target

Esperion Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $8.

CORRECTION: Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Overweight rating and announces Price Target of $8. -Analyst Firm Updated

CORRECTION: Cantor Fitzgerald Initiates Coverage On Esperion Therapeutics with Overweight Rating, Announces Price Target of $8 -Analyst Firm Updated

Wedbush analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Overweight rating and announces Price Target of $8.

Wedbush Initiates Coverage On Esperion Therapeutics with Overweight Rating, Announces Price Target of $8

<h3>Gainers</h3>
<ul>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 18.7% to $4.31 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) shares rose 16.0% to $0.5. The market value of their outstanding shares is at $297.7 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock rose 15.81% to $2.49. The market value of their outstanding shares is at $28.6 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) stock rose 13.62% to $13.18. The company's market cap stands at $21.8 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 13.33% to $3.91. The company's market cap stands at $3.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock moved upwards by 12.82% to $0.93. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock decreased by 41.0% to $2.34 during Friday's pre-market session. The market value of their outstanding shares is at $99.5 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares declined by 32.48% to $2.54. The company's market cap stands at $66.2 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock fell 30.62% to $6.8. The market value of their outstanding shares is at $220.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares fell 20.84% to $0.19. The company's market cap stands at $20.5 million. </li>
<li>Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) stock declined by 15.77% to $16.94. The company's market cap stands at $1.1 billion. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares decreased by 14.15% to $2.19. The market value of their outstanding shares is at $431.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCYC

BRNS

CADL

CVKD

ISPC

LTRN

RPTX

SENS

12 Health Care Stocks Moving In Friday's Pre-Market Session

Press Releases

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

Management

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

Comments

Esperion Therapeutics

Noticias

Últimas noticias sobre Esperion Therapeutics (NASDAQ:ESPR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL